Products
Cyclopentolate is commercially available in the form of eye drops (cyclogyl). It has been approved in many countries since 1968.
Structure and properties
Cyclopentolate (C17H25NO3, Mr = 291.4 g/mol) is present in drugs as cyclopentolate hydrochloride, a white crystalline powder. It is a racemate and a derivative of atropine, which is used for the same indications.
Effects
Cyclopentolate (ATC S01FA04) has anticholinergic, pupil dilating, and accommodation paralyzing properties. Underlying the effects is blockade of the sphincter muscle of the iris and the accommodative muscle. Compared to atropine, the effects occur more rapidly and last less time, between 6 to a maximum of 24 hours. Rarely, they may last a few days.
Indications
To achieve mydriasis (dilation of the pupil) and cycloplegia (paralysis of accommodation).
Dosage
According to the SmPC. For use under medical supervision, see also Administering eye drops.
Contraindications
- Hypersensitivity
- Narrow angle glaucoma or anatomically narrow angle
Refer to the drug label for complete precautions.
Interactions
Carbachol and pilocarpine may reverse the effects of cyclopentolate and vice versa.
Adverse effects
Possible adverse effects include transient local reactions such as burning sensation, increased intraocular pressure, photosensitivity, blurred vision, eye irritation, increased blood flow, eyelid and conjunctivitis, keratitis punctata, and synechiae. Systemic side effects, such as central disorders, are possible, especially in children.
